Harouaka et al., 2014 - Google Patents
Circulating tumor cells: advances in isolation and analysis, and challenges for clinical applicationsHarouaka et al., 2014
View PDF- Document ID
- 857987280303639557
- Author
- Harouaka R
- Kang Z
- Zheng S
- Cao L
- Publication year
- Publication venue
- Pharmacology & therapeutics
External Links
Snippet
Circulating tumor cells (CTCs) are rare cancer cells released from tumors into the bloodstream that are thought to have a key role in cancer metastasis. The presence of CTCs has been associated with worse prognosis in several major cancer types, including breast …
- 208000005443 Circulating Neoplastic Cells 0 title abstract description 348
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Harouaka et al. | Circulating tumor cells: advances in isolation and analysis, and challenges for clinical applications | |
| Liberko et al. | Essentials of circulating tumor cells for clinical research and practice | |
| Guiu et al. | Invasive lobular breast cancer and its variants: how special are they for systemic therapy decisions? | |
| Wang et al. | Protein mislocalization: mechanisms, functions and clinical applications in cancer | |
| Alegre et al. | Circulating biomarkers in malignant melanoma | |
| Torino et al. | Circulating tumor cells in colorectal cancer patients | |
| Nienhuis et al. | Targeting breast cancer through its microenvironment: current status of preclinical and clinical research in finding relevant targets | |
| WO2018081625A3 (en) | Digital analysis of blood samples to determine efficacy of cancer therapies for specific cancers | |
| JP2014144959A5 (en) | ||
| HK1213924A1 (en) | Combination of anti-kir and anti-ctla-4 antibodies to treat cancer | |
| Niu et al. | Dual roles of orphan nuclear receptor TR3/Nur77/NGFI-B in mediating cell survival and apoptosis | |
| HK1255533A1 (en) | Protein biomarker panels for detecting colorectal cancer and advanced adenoma | |
| MX2019012260A (en) | Dna methylation and mutational analysis methods for bladder cancer surveillance. | |
| WO2015052583A3 (en) | Method for the prognosis and treatment of metastasizing cancer of the bone originating from breast cancer | |
| WO2011112903A3 (en) | Quantitative rt-pcr detection for genes involved in epithelial mesenchymal transition in peripheral blood of breast cancer patients | |
| WO2014184679A3 (en) | Method for the prognosis and treatment of renal cell carcinoma metastasis | |
| GB2523211A8 (en) | MCT protein inhibitor-related prognostic and therapeutic methods | |
| Hollande et al. | The long road to colorectal cancer therapy: searching for the right signals | |
| Lopez-Munoz et al. | Markers of circulating breast cancer cells | |
| EA201890816A1 (en) | OPTION 7AS ANDROGENOVA RECEPTOR AS A BIOMARKER FOR THE CHOICE OF TREATMENT OF PATIENTS WITH METASTATIC PROSTATE CANCER RESISTANT TO CASTRATION (MCRPC) | |
| EA201501095A1 (en) | EFFECTIVE TREATMENT OF NSCLC AND A PREDICTIVE CLINICAL MARKER OF SENSITIVE TREATMENT TO TUMOR | |
| Fennell et al. | Association between gene expression profiles and clinical outcome of pemetrexed-based treatment in patients with advanced non-squamous non-small cell lung cancer: exploratory results from a phase II study. | |
| Zhe et al. | Value of circulating tumor cells in early monitoring of bladder cancer micrometastases | |
| WO2015193738A3 (en) | Methods and biomarkers for analysis of colorectal cancer | |
| Ueki et al. | Preliminary Analysis of Pretreatment Diffusion-Weighted MRI and 18F-FDG PET/CT as Prognostic Factors in Patients With Non-Small Cell Lung Cancer Receiving Stereotactic Body Radiation Therapy |